Journal
FRONTIERS IN ONCOLOGY
Volume 10, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fonc.2020.01221
Keywords
GSK3 beta; Tregs; IL-10; NFAT2; PD-L1
Categories
Ask authors/readers for more resources
Immunotherapy options for patients with cancer have emerged following decades of research on immune responses against tumors. Most treatments in this category harness T cells with specificity for tumor associated antigens, neoantigens, and cancer-testis antigens. GSK3 beta is a serine-threonine kinase with the highest number of substrates and multifaceted roles in cell function including immune cells. Importantly, inhibitors of GSK3 beta are available for clinical and research use. Here, we review the possible role of GSK3 beta in the immune tumor microenvironment, with goal to guide future research that tests GSK3 beta inhibition as an immunotherapy adjunct.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available